Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | LGMN | Q99538 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286791 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2MAPK1LMNAALDH1A1MAPT | |
| SCHEMBL6286338 | 0.88 | SMN1; SMN2 (0.40) | SMN1; SMN2MAPK1LMNAALDH1A1MAPT | |
| SCHEMBL6289522 | 0.88 | SMN1; SMN2 (0.40) | SMN1; SMN2MAPK1LMNAALDH1A1MAPT | |
| SCHEMBL6289981 | 0.88 | SMN1; SMN2 (0.40) | SMN1; SMN2MAPK1LMNAALDH1A1MAPT | |
| SCHEMBL6286332 | 0.88 | SMN1; SMN2 (0.40) | SMN1; SMN2MAPK1LMNAALDH1A1MAPT | |
| SCHEMBL6289523 | 0.88 | SMN1; SMN2 (0.40) | SMN1; SMN2MAPK1LMNAALDH1A1MAPT | |
| SCHEMBL6287628 | 0.83 | NOTUM (0.37) | SMN1; SMN2MAPK1LMNAALDH1A1MAPT | |
| SCHEMBL6286693 | 0.83 | NOTUM (0.37) | SMN1; SMN2MAPK1LMNAALDH1A1MAPT | |
| SCHEMBL6289970 | 0.83 | MAPK1 (0.36) | SMN1; SMN2MAPK1LMNAALDH1A1MAPT | |
| SCHEMBL6286691 | 0.83 | NOTUM (0.37) | SMN1; SMN2MAPK1LMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059685-A1 | Pyridopyrimidine compounds and their uses | CELL THERAPEUTICS, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-6825180-B2 | CYTOKINE INTRACELLULAR SIGNALING INHIBITORS; ANTIINFLAMMATORY AGENTS | CELL THERAPEUTICS, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20040023995-A1 | Pyridopyrimidine compounds and their uses | CELL THERAPEUTICS, INC. | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023995-A1 | Pyridopyrimidine compounds and their uses | PLPBP, MAVS, PDXK | SMN1; SMN2 1228/4885MAPK1 97/4885LMNA 3136/4885 |
| US-20050059685-A1 | Pyridopyrimidine compounds and their uses | PLPBP, MAVS, PDXK | SMN1; SMN2 1228/4885MAPK1 97/4885LMNA 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.